These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25773385)

  • 21. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.
    Hong JY; Park YH; Choi MK; Jung HA; Lee SJ; Ahn JS; Im YH
    Clin Breast Cancer; 2015 Oct; 15(5):e287-92. PubMed ID: 25997855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
    Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
    BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
    Dao BD; Ho H; Quintal LN
    J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
    Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
    Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
    Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [GRP78 expression in gastric cancer and its clinical significance].
    Yang L; Yang SY; Ji JM; Cao YF; Ji CF; Ji JF; Xu WW; Wang JH
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):837-42. PubMed ID: 24447482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer.
    Kishida Y; Tsushima T; Endo M; Hamauchi S; Todaka A; Yokota T; Machida N; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
    Am J Clin Oncol; 2018 Jan; 41(1):41-45. PubMed ID: 26422718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
    Baquero MT; Lostritto K; Gustavson MD; Bassi KA; Appia F; Camp RL; Molinaro AM; Harris LN; Rimm DL
    Breast Cancer Res; 2011 Nov; 13(5):R85. PubMed ID: 21888627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.
    Valet F; de Cremoux P; Spyratos F; Servant N; Dujaric ME; Gentien D; Lehmann-Che J; Scott V; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Pierga JY; Delaloge S; Giacchetti S; Brain E; Tembo O; Marty M; Asselain B
    Breast; 2013 Dec; 22(6):1052-9. PubMed ID: 24095610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent radiotherapy and taxane chemotherapy in patients with locoregional recurrence of breast cancer. A retrospective analysis.
    Semrau S; Gerber B; Reimer T; Klautke G; Fietkau R
    Strahlenther Onkol; 2006 Oct; 182(10):596-603. PubMed ID: 17013573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 20-gene signature in predicting the chemoresistance of breast cancer to taxane-based chemotherapy.
    He DX; Xia YD; Gu XT; Jin J; Ma X
    Mol Biosyst; 2014 Dec; 10(12):3111-9. PubMed ID: 25209432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.
    Spicakova T; O'Brien MM; Duran GE; Sweet-Cordero A; Sikic BI
    Mol Cancer Ther; 2010 Nov; 9(11):2970-81. PubMed ID: 21062914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
    Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
    Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
    Pachmann K; Dengler R; Lobodasch K; Fröhlich F; Kroll T; Rengsberger M; Schubert R; Pachmann U
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):59-65. PubMed ID: 17611779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
    Samimi G; Ring BZ; Ross DT; Seitz RS; Sutherland RL; O'Brien PM; Hacker NF; Huh WK
    Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):273-9. PubMed ID: 22194527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I; Lindborg K; Sorbe B
    Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.